Antibody Agreements Reviewed in New CurrentPartnering Study Now Available at MarketPublishers.com

Share Article

New research study “Antibody Partnering Terms and Agreements” worked out by CurrentPartnering has been recently published by Market Publishers Ltd.

TD The Market Publishers Ltd

http://marketpublishers.com/

What are the precise antibody rights granted or optioned? What is actually granted by the agreement to the partner company? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The answers to all these crucial questions and many more are available in the research study.

New research study “Antibody Partnering Terms and Agreements” worked out by CurrentPartnering has been recently published by Market Publishers Ltd.

Report Details:

Title: Antibody Partnering Terms and Agreements
Published: March, 2012
Pages: 1023
Price: US$ 2,695
http://marketpublishers.com/report/medicine_pharmaceuticals_biotechnology/healthcare_equipment_services/antibody_partnering_terms_n_agreements.html

The research study is designed to provide an in-depth understanding and unprecedented access to the antibody partnering deals and agreements entered into by the top healthcare companies worldwide, as well as explaining how and why these companies enter these deals. In particular, the report covers:

  •     Antibodies
  •     Antibody-drug conjugates
  •     Monoclonal antibodies

o    Murine mAb
o    Chimeric mAb
o    Humanized mAb
o    Human aAb
o    Polyclonal Antibodies

  •     Trends in antibody dealmaking in the biopharma industry since 2007
  •     Antibody partnering agreement structure
  •     Case studies of real-life antibody deals
  •     Antibody partnering contract documents (over 1500)
  •     Top antibody deals by value since 2007
  •     Most active antibody dealmakers since 2007

The available deals are listed by: company A-Z; headline value; stage of development at signing; deal component type; specific therapy target; and specific antibody type.

Report Contents:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in Antibody Dealmaking

2.1. Introduction
2.2. Antibody partnering over the years
2.3. Bigpharma antibody dealmaking activity
2.4. Bigpharma not active in antibody partnering
2.5. Antibody partnering by deal type
2.6. Antibody partnering by disease type
2.7. Partnering by antibody type
2.8. Average deal terms for antibody partnering
2.8.1 Antibody headline values
2.8.2 Antibody upfront payments
2.8.3 Antibody milestone payments
2.8.4 Antibody royalty rates

Chapter 3 – Leading Antibody Deals

3.1. Introduction
3.2. Top antibody deals by value
3.3. Top antibody deals involving bigpharma

Chapter 4 – Bigpharma Antibody Deals

4.1. Introduction
4.2. How to use bigpharma antibody partnering deals
4.3. Bigpharma antibody partnering company profiles
Abbott
Actavis
Alcon Labs
Allergan
Amgen
Apotex
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Kyowa Hakko Kirin
Lundbeck
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Roche
Sanofi
Servier
Shionogi
Stada
Takeda
Teva
UCB
Warner Chilcott
Watson

Chapter 5 – Antibody Dealmaking Directory

5.1. Introduction
5.2. Company A-Z
5.3. By stage of development
Discovery
...

More new studies by the publisher can be found at CurrentPartnering page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tanya Rezler
Visit website